---
name: pivot-sequencing
description: >
  Design multi-year transition plans — what to do in year 1 to make year 3 possible,
  intermediate roles, advisor seats, side artifacts, and the order that makes the move
  credible. Reference when the target archetype is multi-year away, when an obvious
  direct-path is unavailable, or when the user is choosing between fast-and-risky and
  slow-and-credible paths. Most senior pivots are not single moves; they are sequences.
metadata:
  author: nirav
  version: "1.0"
compatibility: Designed for Claude Code
allowed-tools: Read
---

# Pivot Sequencing — Multi-Year Choreography of a Transition

The biggest pivot mistake is treating a multi-year transition as a single move. The senior MD who decides to "become a VC" and starts cold-applying at firms that recruit only consulting/finance backgrounds at the associate level. The path exists, but it's not direct — it requires sequencing: a year of deliberate public-artifact production, a venture-partner or operating-partner stint, an EIR role at a firm, and only then a partner-level conversation. The sequencing is the work; the destination is downstream.

## Key Concepts

### Direct-Path vs Sequenced-Path

| Direct-Path | Sequenced-Path |
|---|---|
| Target role exists; user has the credentials; apply directly | Target role requires capabilities user doesn't yet have; intermediate moves required |
| 6–18 month transition | 2–5 year transition |
| Single offer / negotiation | Multiple intermediate decisions, each with optionality consequences |
| Optionality not a major concern (move is committed) | Optionality preservation matters at each stage |

For an MD targeting biotech VC, the direct path is often unavailable (associate pools select for consulting/finance/prior-VC; partner-level requires existing track record). The sequenced path is the real path; planning for it is the work.

### The Intermediate Role Categories

Common intermediate roles for an MD → biotech VC transition:

| Intermediate Role | What It Does for the Trajectory | Time Cost |
|---|---|---|
| **Senior operator role at a venture-backed company** (CMO, Head of Clin Dev) | Builds operator credibility VCs respect; works alongside investor-facing work | 1–3 years |
| **Founding role / co-founder** | Builds founder pattern; some firms prefer ex-founders for partner roles | 2–5 years |
| **Independent advisor (multiple boards)** | Builds advisory credibility, network, and reputation | Compounds over time |
| **EIR at a venture firm** | Direct exposure to firm operations; insider track to partner role | 6–18 months |
| **Operating partner at a venture firm** | Hybrid role; partner-adjacent without committing to full investor track | 2+ years |
| **Venture partner (part-time)** | Lower commitment; lets user maintain operating role while building VC credibility | 1–3 years |

Many sequenced paths involve one or more of these intermediate roles, often with overlapping time-spans (advisor while operating; venture partner while operating).

### The Year-1 / Year-3 Frame

For a multi-year pivot, design:

| Horizon | Goal | Output |
|---|---|---|
| **Year 1** | Build the credibility that makes year 3 possible | Public artifacts, network depth, intermediate role |
| **Year 2** | Convert credibility into proof points | Specific roles taken, investments, advisor seats, named achievements |
| **Year 3** | Move into the target archetype | Direct conversation with target firms / roles |

The year-1 work is invisible from the outside — it doesn't look like progress toward the target. The discipline to do it anyway is the differentiator.

### The Side-Artifact Track

Side artifacts (public artifacts produced outside the user's day job) are a parallel track that runs throughout the sequence:

- **Year 1**: One flagship artifact (essay, repo, talk) that announces the trajectory
- **Year 2**: Sustained cadence — quarterly substantive output
- **Year 3**: Recognized as a thinker in the space; cited by others

The artifact track compounds independently of the role track and provides the public proof points that intermediate roles often don't surface.

### Sequence-Risk vs Pace-Risk

| Risk Type | What It Looks Like | Mitigation |
|---|---|---|
| **Sequence risk** | The intermediate role doesn't lead where you expected | Choose intermediate roles for both intrinsic value and trajectory value |
| **Pace risk** | The transition takes longer than expected; opportunity cost mounts | Set explicit pace-checkpoints; if unmet, reassess |
| **Optionality decay** | Each step closes more options; trajectory becomes irreversible | Preserve optionality early; commit late |
| **Burnout** | Multi-year sustained transition work is exhausting | Sustainable pace; rest cycles built in |

### The Honest Timeline

Most senior professionals over-estimate pace and under-estimate sequence work. A 5-year sequenced transition is common for major archetype shifts (MD → biotech VC partner; senior operator → founder → repeat-founder). Expecting a 1–2 year direct-path when a 4–5 year sequenced-path is the realistic shape produces frustration and short-cut errors.

### Common Failure Modes

| Failure | Looks Like | Fix |
|---|---|---|
| Direct-path attempt for sequenced-path target | Cold-applying for VC associate roles at firms that don't take operators | Recognize the regime; design the sequence |
| No intermediate-role plan | "Eventually I'll be a VC partner" with no path | Identify viable intermediate roles |
| Side-artifact track ignored | Pivot through roles only, no public output | Add the artifact track |
| Pace-impatience | Quitting the sequence after 12 months | Honor the multi-year horizon; checkpoint at 12, 24, 36 |
| Optionality forfeit too early | First intermediate role is highly committing | Preserve optionality early in the sequence |

## Self-Coaching Track

**For your situation (MD → biotech VC/operator):**

1. **Name the realistic timeline.** For your top archetype (e.g., biotech VC partner-track), be honest: is this a 2-year direct-path or a 4–5 year sequenced-path? For most senior MDs targeting VC partner, it's the latter.

2. **Identify viable intermediate roles.** From the table, which 2–3 intermediate roles are realistic for you in the next 12–24 months? Not aspirational — viable.

3. **Plan the side-artifact track.** What flagship artifact will you produce in year 1? What's the cadence in year 2? Schedule the deliverables.

4. **Map the year-1 / year-3 plan.** Year 1: what credibility builds? Year 2: what proof points? Year 3: what conversations? Be specific.

5. **Identify sequence-risk per intermediate role.** For each candidate intermediate role, does it lead where you expect? What if it doesn't?

6. **Build pace-checkpoints.** At month 12, 24, 36 — what specific signals indicate the sequence is working? What would tell you to reassess? Cross-load with `idp-and-okrs` for the operating cadence.

7. **Sustainability check.** Is the planned pace sustainable across 3+ years? Where are the rest cycles? Where might the burnout risk be highest?

## Teach / Mentor-Others Track

**When coaching a junior or peer through pivot sequencing:**

1. **Reframe from move to sequence.** Mentees default to single-move thinking. The reframe to multi-year sequence is uncomfortable but accurate.

2. **The intermediate-role catalog is high-leverage.** Many mentees haven't seen the catalog. Walk through the table; reveal options they hadn't considered.

3. **Side-artifact track is undervalued.** Many mentees focus on roles and ignore artifacts. Coach the parallel track; show how artifacts compound independently.

4. **The honest-timeline conversation is hard but essential.** Mentees often want a 2-year answer when 4 years is realistic. The honest reframe is uncomfortable; do it.

5. **Pace-checkpoints prevent both impatience and stagnation.** Coach mentees to set explicit checkpoints. Without them, they'll either quit the sequence at 12 months or stay too long when the sequence isn't working.

6. **Coach against "wait until I'm ready" framing.** Some mentees use sequence-thinking as procrastination. The right reframe: start the sequence now; the readiness emerges from doing the sequence.

## When This Applies

- Designing a multi-year career transition
- Choosing among intermediate role candidates
- Annual review of progress against the sequence
- After unexpected disruption (job loss, role change) that requires re-sequencing
- When considering whether to attempt a direct-path or commit to sequenced-path

## Cross-Domain Connections

- **trajectory-design/role-archetype-mapping** — Sequence destination is the chosen archetype
- **trajectory-design/skill-gap-analysis** — Sequence stages close named gaps
- **trajectory-design/optionality-architecture** — Each stage in the sequence has option-set consequences
- **trajectory-design/idp-and-okrs** — Sequence stages translate to annual IDPs / quarterly OKRs
- **personal-positioning/public-portfolio** — Side-artifact track lives here
- **network-cultivation/ecosystem-mapping** — Intermediate roles often emerge from network discovery